REFERENCES
- Gu D, Reynolds K, Wu X, Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005;365:1398–1405.
- Deedwania PC. Endothelium: a new target for cardiovascular therapeutics. J Am Coll Cardiol 2000;35:67–70.
- Celemajer DS, Sorensen KE, Gooch VM, Non-invasive detection of endothelial dysfunction in children and in adults at risk of artherosclerosis. Lancet 1992;340: 1111–1115.
- National task force on the prevention and treatment of obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996;276:1907–1915.
- Davidson MH, Hauptman J, Digirolamo M, Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235–242.
- Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002;20:2257–2267.
- Pi-Sunyer FX. Short-term medical benefits and adverse effects of weight loss. Ann Intern Med 1993;119:722–726.
- Joannides R, Haefeli WE, Linder L, Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91: 1314–1319.
- Iiyama K, Nagano M, Yo Y, Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J 1996;132:779–782.
- Hashimoto M, Akishita M, Eto M, The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation. Int J Obes Relat Metab Disord 1998;22: 477–484.
- Sekuri C, Tavli T, Avsar A, Sozcuer H, Uyanik BS, Ari Z. The acute effect of orlistat on endothelial function in young obese women. Int J Clin Pharmacol Res 2003;23: 111–117.
- Brook RD, Bard RL, Glazewski L, Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. Am J Cardiol 2004;93:1012–1016.
- Sciacqua A, Candigliota M, Ceravolo R, Weight loss in combination with physical activity improves endothelial dysfunction in human obesity. Diabetes Care 2003;26:1673–1678.
- Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000;49:1231–1238.
- Bhagat K, Balance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997;96:3042–3047.
- Browne CD, Hindmarsh EJ, Smith JW. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J 2006;20:2027–2035.
- Samuelsson L, Gottsater A, Lindgarde F. Decreasing levels of tumour necrosis factor [alpha] and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes, Obesity & Metabolism 2003;5:195–201.
- Tong PC, Lee ZS, Sea MM, The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002; 162:2428–35.
- Bergholm R, Tiikkainen M, Vehkavaara S Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care 2003;26:1667–1672.
- Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognositic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002;40:505–510.
- Moriguchi J, Itoh H, Harada S, Low frequency regular exercise improves flow-mediated dilatation of subjects with mild hypertension. Hypertens Res 2005;28:315–321.